| LYNBROOK, N.Y., Feb. 23, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has entered into a partnership with Actelion Pharmaceuticals Ltd. (Actelion) for the long-term development, supply and commercialization of XIAFLEX for the treatment of Dupu...continued ALIOY AUXL BSTC collagen aponeurotomy dupuytrens |
Thursday, February 23, 2012
BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX( in Canada, Australia, Brazil and Mexico
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment